FSP + FLASCO 2024 Meeting

Our ambition is to push the boundaries of science to change the practice of medicine and transform the lives of cancer patients. We target the underlying biology of cancer in Immuno-Oncology, Tumor Drivers/Resistance, DNA Damage Response and Antibody Drug Conjugates. Utilizing precision medicine and biomarker-driven indications we look to dramatically improve five-year survival. Our focus on early disease stages and relapsed patients is to 1) identify and treat patients earlier with curative intent; and 2) support relapsed and refractory patients by tackling primary or acquired resistance.

With its revolutionary and proprietary Idylla™ platform, Biocartis aspires to enable personalized medicine for patients around the world through universal access to molecular testing, by making molecular testing actionable, convenient, fast and suitable for any lab. The Idylla™ platform is a fully automated sample-to-result, real-time PCR based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster, informed treatment decisions. Idylla™'s continuously expanding menu of molecular diagnostic tests address key unmet clinical needs, with a focus in oncology. Today, Biocartis offers tests supporting lung, melanoma, colorectal, AML and Glioma. 

Blueprint Medicines is a global precision therapy company that aims to invent transformative medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we seek to create therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy.

Caris Life Sciences® (Caris) is the leading next-generation AI TechBio company and precision medicine pioneer actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI. Through comprehensive molecular profiling (DNA, RNA and proteins) and the application of AI and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This provides an unmatched platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. To learn more, please visit www.CarisLifeSciences.com.

Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Co., Ltd., is headquartered in Basking Ridge, New Jersey, and is focused on the development and delivery of oncology and specialty medicines. Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for metastatic breast, lung and gastric cancer, tenosynovial giant cell tumor and iron deficiency anemia.

We believe every patient living with advanced cancer should benefit from comprehensive genomic information to inform their care. That’s why we’ve built a powerful portfolio of comprehensive genomic profiling (CGP) tests that—via both blood and tissue samples—evaluate more than 300 genes known to drive cancer. For more information, visit our website www.foundationmedicine.com

Powered by pioneering science, grounded in world-class expertise, and driven by purpose, Geron aims to change lives by changing the course of blood cancer.

Unlocking Insights to Help Find, Treat, and Monitor Cancer

Today our proprietary blood tests are helping to realize the full potential of precision oncology by providing patients and their doctors critical insights that can inform decisions at all stages of the disease, from screening, to monitoring cancer recurrence, to treatment decisions.
In advanced cancer, our Guardant Complete portfolio has helped to accelerate adoption of precision medicines, or targeted therapies, which have made a radical difference in improving outcomes for patients battling advanced cancer. The number of FDA-approved therapies grows each year, and our blood tests enable guideline recommended complete genomic testing in order to help match patients to these targeted therapies. Guardant 360 Response™ can also monitor a patient’s response to treatment, to help doctors refine treatment even further.

Targeting a better life for people with cancer is why we get up in the morning. It’s not enough to disrupt the progress of someone’s cancer; we want to keep cancer from disrupting someone’s life. That’s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives – back to living today, tomorrow, and beyond. For us, targeting a better now is the only thing that matters.

Molecular diagnostic testing for indeterminate thyroid nodules utilizing multi platform testing. ThyGeNEXT is an oncogenic mutation panel that helps identify malignant thyroid nodules and ThyraMIR is a proprietary microRNA gene expression assay that helps to clarify the risk of cancer in thyroid nodules.

The J&J Precision Medicine team is committed to advancing knowledge around a biomarker informed cancer care continuum. We are marketers, value and access, data scientists, lab clinicians, scientists, pathologists, and pharmacists who partner with our customers to alleviate practice gap roadblocks through education, partnerships, and projects. 

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Signatera is a personalized, tumor-informed assay, optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer. Results are based on the unique signature of a patient’s tumor by tracking mutations at the source and enabling accurate monitoring of disease over time. Clinically validated in multiple cancer types, Signatera is covered by Medicare for colorectal cancer (CRC), muscle invasive bladder cancer (MIBC), and stage IIb and higher breast cancer in both the adjuvant and surveillance setting as well as monitoring response to immunotherapy treatment for any solid tumor. Discover more at: natera.com/oncology      

NeoGenomics is a Florida-based premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic, and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-certified facilities in the US and offer global capabilities with laboratories in Switzerland and Singapore. 

We’re in relentless pursuit of breakthroughs that change patients’ lives. We innovate every day to make the world a healthier place. It was Charles Pfizer’s vision at the beginning and it holds true today. For more information please visit Homepage (pfizeroncologytogether.com)

As the world’s leading provider of diagnostic information services, Quest Diagnostics and all our employees are committed to The Quest Way, sharing our purpose, strategy, and culture—through working every day to uncover important insights about your health. We’re dedicated to providing actionable results that empower you with the information you need to make your healthcare decisions count through:

-Discovering new ways to screen for, prevent, diagnose, and monitor disease
-Making it faster and easier for consumers, patients, doctors, and hospitals to access lab tests and data when they need it
-Ensuring patients obtain the services and care they need when they need it
-Solving health inequities and working collaboratively to make communities healthier

At Recordati Rare Diseases, we are Focused on the Few. Rare diseases aren’t just in our name: they are at the core of all that we do. We work side-by-side with rare disease communities to raise awareness, educate, and advocate for improved diagnosis. Together, we can celebrate our successes and strengthen our impact for people living with rare diseases.

Founded in 2006, Vitro Molecular Laboratories is dedicated to providing unparalleled quality and accuracy in cancer diagnostics. Driven by a patient-focused and highly experienced medical and technical team, Vitro enhances your lab capabilities with a comprehensive test menu and industry-leading turnaround times.
Vitro’s focus is on serving the pathology and oncology community by offering a robust menu of Immunohistochemistry (IHC) , FDA-cleared Flow Cytometry, FISH,  Molecular testing, along with tissue processing and block preparation capabilities. Many of our services are available as tech-only as well as globally. We also specialize in consultative workups for your most challenging cases, web-based digital pathology and virtual tumor boards.
Our commitment to exceptional customer service, quality, and cost-effective testing has made Vitro a top-tier anatomical pathology service provider, proven by the loyalty of our clients and the positive impact we make in the care of their patients.